In current study, we provided evidence that serum HSP90α was a potential biomarker for evaluating the power of diagnosis and short-term prognosis of patients with sepsis, which could assist clinician identification of sepsis at early stage and lay the groundwork for the development of novel therapeutic target for patients with sepsis. Here, HSP90AA1 is linked to Sepsis.